Personalis expands Tempus partnership to colorectal cancer MRD; term to 2029

Personalis, Inc.

Tempus authorized to market NeXT Personal MRD test for colorectal cancer, fourth indication.
Agreement term extended to November 25, 2029.
Exclusivity period extended to December 31, 2028 for both parties on tumor-informed MRD in these indications.
Standstill restrictions for Tempus modified to expire June 4, 2027 or end of exclusivity.

item 1.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.